A gluten-free diet is the most important therapy for coeliac disease patients. Beyond the psychological and social burden of maintaining a strict gluten-free diet, minimal gluten intake cannot be avoided. Minimal ingestion of gluten can already cause symptoms in 30% of the patients, according to Prof. Detlef Schuppan (Mainz University Medical Center, Germany). Therefore, a supportive pharmacological therapy is needed. Currently there is no effective or approved drug for coeliac disease. A phase 2a trial examined ZED-1227, an irreversible transglutaminase-2 inhibitor, among 160 coeliac patients in remission who followed a gluten-free diet [1]. All patients were to eat a standardised cookie with 3 g gluten daily for 6 weeks and were randomised to 10 mg, 50 mg, or 100 mg of ZED-1227 (oral, once daily), or placebo. Primary endpoint was histological damage, represented by villus height to crypt depth ratio.
Patients in all ZED-1227 conditions showed significantly improved villus height to crypt depth ratios compared with patients receiving placebo (P<0.001). Similarly, the intraepithelial lymphocyte (IEL) density was significantly lower in the ZED-1227 groups, compared with placebo. Other secondary endpoints, such as the Celiac Disease Questionnaire Gastrointestinal (CDQ GI) symptom subscore, transglutaminase-2 autoantibodies, and markers of inflammation showed patient benefits for the ZED-1227 subjects. To conclude, no relevant side effects were reported in this trial.
- Schuppan D, et al. Oral inhibitor of transglutaminase 2 prevents mucosal damage in coeliac patients undergoing gluten challenge. LB06, UEG Week 2021 Virtual Congress, 03–05 October.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Serologic response to COVID-19 mRNA vaccine reduced in IBD patients on anti-TNFα Next Article
Ritlecitinib and brepocitinib are promising JAK inhibitors for UC »
« Serologic response to COVID-19 mRNA vaccine reduced in IBD patients on anti-TNFα Next Article
Ritlecitinib and brepocitinib are promising JAK inhibitors for UC »
Table of Contents: UEGW 2021
Featured articles
Updates in Biologics
Risankizumab meets primary endpoints in maintenance study for CD patients
Ustekinumab treat-to-target strategy offers long-term alternative for standard-of-care in CD
Long-term efficacy data of dupilumab for eosinophilic oesophagitis
Updates in Small Molecules
Upadacitinib efficacious and safe as maintenance therapy for UC
Upadacitinib outperforms placebo in UC patients with inadequate response to biologics
Rapid symptom control for UC patients on upadacitinib
Filgotinib demonstrates promising results for various lines of therapy in UC
Filgotinib demonstrates long-term corticosteroid-sparing effects in UC
Long-term benefits of tofacitinib for substantial proportion of UC patients
Ritlecitinib and brepocitinib are promising JAK inhibitors for UC
First pharmacological therapy with clear efficacy in coeliac disease patients
Endoscopy
Motorised spiral enteroscopy safe in real-life and in patients with altered anatomy
Novel tool can reliably exclude submucosal invasion in colorectal polyps
Other Updates
Serologic response to COVID-19 mRNA vaccine reduced in IBD patients on anti-TNFα
Serious adverse events put a stop to ASTIClite trial for CD
Related Articles
April 14, 2020
Clinical remission after dose escalation of upadacitinib
April 14, 2020
On the cutting edge of pathology and surgery
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com